STLN · Starling Oncology

The thesis

Starling Oncology's shares are more likely to lag the S&P 500 over the next three months. On 5 November 2026 the company cut its 2026 capitated-revenue outlook to about $110 million from about $150 million, and a 10% owner sold 2,851,061 shares the next day. The fourth-quarter report, expected around March 2027, settles the case: it shows whether the Florida contracts deliver the guided $3 million to $5 million of adjusted earnings before interest, taxes, depreciation and amortization (EBITDA), and what 2027 guidance says about capitated growth.

Under capitation, the company receives a fixed monthly payment for each covered patient and pays for that patient's cancer care. Margins widen when medical costs run below the payment and shrink when they run above it.

The 5 November report beat on profit and fell short on growth. Third-quarter adjusted EBITDA was $3.4 million, against guidance of $500,000 to $1.5 million. The release blamed the lower capitated outlook on delayed statewide expansion with certain Florida partners. The shares fell from $6.70 on 5 November 2026 to $3.62 on 6 November 2026 and closed at $4.20 on 11 November 2026. At that price, the market is pricing the growth shortfall. It gives little weight to the Buy ratings and the $8 to $10 targets that BTIG, B. Riley and Lake Street kept after the report.

The rating is Low because the growth part of the case now depends on Florida timing that the company has already pushed back once. A large holder has also been selling into the fall. The next hard test of either is months away.

Bullish and bearish views on Starling Oncology, Inc.

The bull case on Starling Oncology, Inc. (STLN), in brief: profit beat its own guidance. The bear case: the capitated outlook came down.

Bull case

• Profit beat its own guidance. Third-quarter 2026 adjusted EBITDA was $3.4 million, against a $3.5 million loss a year earlier, per the 5 November 2026 release. It was the second straight positive quarter.
• Gross profit outran revenue. Revenue was $169.8 million, up 24.3% year over year, and gross profit was $30.7 million, up 62.1%, per the same release. The 12 November 2026 investor presentation guides 2026 gross profit to $107 million to $110 million.
• The profit floor moved up. The release raised the low end of FY2026 adjusted EBITDA guidance to $4 million from $2 million and guided fourth-quarter adjusted EBITDA to $3 million to $5 million.
• Medical costs eased from the second quarter. The medical loss ratio, the share of capitated revenue spent on care, was 81.0% in the third quarter against 85.5% in the second, per the release. The 12 November 2026 presentation expects it to settle at 75% to 85% at run rate.
• The debt was refinanced. The 12 November 2026 presentation says the $86 million Deerfield note was repaid through a refinancing with OrbiMed, with revolving credit capacity expanded to $25 million.
• Cash generation improved. Nine-month free cash flow was $20.2 million, against negative $26.9 million a year earlier, per the 5 November 2026 release.
• Analysts kept Buy ratings after the fall. B. Riley cut its target to $10 from $11 on 6 November 2026, Lake Street cut its target to $8 from $10 on 7 November 2026, and BTIG reiterated Buy with a $10 target on 9 November 2026, per Benzinga.

Bear case

• The capitated outlook came down. The 5 November 2026 release expects about $110 million of 2026 capitated revenue, against about $150 million in the 6 August 2026 release.
• A 10% owner sold into the drop. Jorey Chernett sold 2,851,061 shares in the open market at $3.99 on 6 November 2026, per a Form 4 filed 10 November 2026. His purchase of 48,294 shares at $3.65 on 9 November 2026 offsets only a small fraction of that.
• Medical costs will rise as Florida lives ramp. The 12 November 2026 presentation guides the medical loss ratio to 85% to 90% over the next 12 months, against 81.0% in the third quarter and 67.8% a year earlier.
• Revenue guidance trailed estimates. FY2026 revenue guidance narrowed to $650 million to $660 million from $650 million to $670 million, against a $663.7 million consensus, per Benzinga on 5 November 2026.
• The per-share loss was wider than expected. The third-quarter loss per share was $0.13, against a $0.05 estimate, per Benzinga on 5 November 2026. The net loss was $15.7 million, including an $11.6 million loss on debt extinguishment.
• Growth leans on pharmacy. Specialty pharmacy revenue rose 44% to $109.3 million at a 24% gross margin, while patient-services revenue slipped 0.3% to $60.0 million, per the 5 November 2026 release.
• The balance sheet is thin. At 30 September 2026, cash was $36.9 million, long-term debt was $72.5 million and the stockholders' deficit was $37.4 million, per the release.

Price setup

The shares closed at $6.70 on 5 November 2026, before the report reached the market. They closed at $3.62 on 6 November 2026. Since then they have closed at $4.00 on 9 November 2026, $4.34 on 10 November 2026 and $4.20 on 11 November 2026.

The last close sits below the 50-day moving average of $6.32 and the 200-day moving average of $4.78, both as of 11 November 2026. A sustained move back over the 200-day average would show buyers absorbing the guidance cut. The shares are down 32.9% over three months from the $6.26 close on 13 August 2026. The last close is 41.1% below the 52-week intraday high of $7.13, set on 18 September 2026. The 52-week closing low is $2.38, from 12 February 2026.

The 10% owner's sale at $3.99 on 6 November 2026 came near the post-report low. The company filed its third-quarter 10-Q on 6 November 2026 and an investor presentation under Regulation FD on 12 November 2026. The presentation repeats the 2026 guidance and adds 2028 targets: about 20% compound annual revenue growth and a mid-single-digit adjusted EBITDA margin. It states no 2027 targets.

Catalysts ahead

• 19 November 2026: Dr. Podnos presents at the APG Fall Conference 2026, per the company's 1 October release. This is the first scheduled management appearance after the third-quarter report. It may give the go-live timing for the delayed Florida contracts and say whether the company still targets 100% capitated revenue growth in 2027.
• ~15 March 2027 (est.): Fourth-quarter and full-year 2026 results. Shows whether adjusted EBITDA reaches the guided $3–5 million and whether the medical loss ratio stays at or under 90%. Formal 2027 guidance will also show whether capitated revenue is still expected to double from about $110 million.

What would change the view

A daily close above $4.91, over the post-report closes of 6 November to 11 November 2026, which would show the shares leading the S&P 500. Fourth-quarter 2026 adjusted EBITDA above the $5 million top of guidance would also prove the call wrong.

What it trades with

Starling Oncology is a small-cap community oncology and specialty pharmacy operator. Company-specific news, such as contract timing, quarterly margins and large-holder Form 4 filings, moves the shares more than broad health-care moves do. Capitation economics tie the company loosely to the Medicare Advantage medical-cost trends that managed-care insurers report. Specialty pharmacy margins tie it to oncology drug pricing. The fall on 6 November 2026 followed the company's own report. Benzinga's health-care pre-market movers list that day showed no matching sector-wide move.